This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Kevzara (sarilumab)
General Description:
Kevzara (sarilumab) is a human monoclonal antibody used for the treatment of moderate to severe rheumatoid arthritis (RA) in adult patients who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).
Sarilumab works by blocking the interleukin-6 (IL-6) receptor, a key driver of inflammation in rheumatoid arthritis. By inhibiting IL-6 signaling, Kevzara helps reduce joint pain, swelling, and long-term joint damage, improving physical function and quality of life for patients.
Disease Indications:
Rheumatoid Arthritis (RA)
Manufacturer:
Sanofi – Aventis Groupe
Usage:
Subcutaneous
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Health Canada
• Therapeutic Goods Administration (TGA)
Package:
• 2 prefilled syringes × 150 mg/1.14 mL
• 2 prefilled syringes × 200 mg/1.14 mL
Shipping:
Cold Chain Shipping
Kevzara contains temperature-sensitive biological ingredients that require protection from heat, light, and improper handling. To ensure product stability and efficacy, it is shipped under cold chain delivery conditions, using specialized medical couriers with temperature-controlled vehicles and packaging.
Although cold chain shipping may be more costly than regular delivery, it ensures that Kevzara remains safe, stable, and fully effective for patient use.
How to Access Kevzara (sarilumab) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Kevzara (sarilumab) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
